Nidanilimab (Nadunolimab)

Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [1][2].

Product Specifications

CAS Number

[2171061-85-9]

Product Name Alternative

CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nidanilimab-nadunolimab.html

Purity

99.90

Solubility

10 mM in DMSO

Smiles

[Nidanilimab(Nadunolimab)]

Molecular Weight

(144.3 kDa)

References & Citations

[1]Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.|[2]Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29.